• Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To analyze the influence of hyperglycemia, diabetes and glycemic variability in the evolution of stroke.To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic factors, extracellular vesicles and remyelinizating drugs. To analyze the contribution of comorbidities in the mechanisms that occur after stroke, and the effect of therapies (protective, reparative ...) in animal models of stroke associated with hypertension, hyperglycemia and diabetes. 

• Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).

• Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, extracellular vesicles) in the ischemic area.

• Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients. 

• Study of the clinical (neurological and neuropsy-chological) and anthropological factors influencing functional recovery and reintegration of stroke pa tients as well as the compliance with the recommendations for secondary stroke prevention.

• To analyze the recovery of post-stroke aphasia through a dubbing tool for television series and the development of a communication app. To evaluate the use of virtual reality in the recovery of motor and cognitive sequelae post-stroke, as well as the computational analysis of movement.

• To evaluate the effectiveness of keeping oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke

• To discover factors anticipating the development of atrial fibrillation through EKG and echocardiographic abnormalities in criptogenic stroke.

• Impact of COVID-19 pandemic in stroke care and in stroke outcomes

• Analysis of Patient Reported Outcome Measures (PROM) and Patient Reported Experience  Measures (PREM) in stroke

• To analyze the differences between general anesthesia and sedation with high flow nasal canula in the endovascular treatment of ischemic stroke.

• Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.

• Central Sensitization and pain perception in patients with cluster headache.

• Features and outcome of migraine in patients with fibromyalgia. 

• Response to OnabotulinumtoxinA in High Frequency Episodic Migraine.  

• Refractory migraine database. 

• Short Term Prophylaxis of Cluster Headache: A Comparative Study.

• Study of neuropathic and chronic craniofacial pain

• Photophobia management using greater occipital nerve blocks in migraine patients

• CGRP-pathway drugs in patients with refractory migraine and medication overuse headache

• CGRP-pathway drugs in patients with refractory migraine and autoinmune diseases

• CGRP-pathway drugs in elderly patients with refractory migraine

• Multicentric colaboration in post-COVID related headache investigation

• Features and outcome of chronic refractory cluster headache treated with greater occipital nerve stimulation

• Cronic cluster headache registry

• Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer’s disease. 

• Study of genetic polymorfism related with PSP in the context of a multicentre Genome Wide Association study (GWAS)

• Tremor as a negative predictive factor in developing dementia associated with Parkinson’s disease.

• Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson’s disease. 

• Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.

• Participation in the Registry of the European Consortium EFACTS (European Friedreich’s Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedrich’s Ataxia.

• Analysis of extracellular vesicles as biomarkers in multiple sclerosis patients. 

• Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis. 

• Search for diagnostic biomarkers, disease monitoring and response to treatment in Multiple Sclerosis

• Development of parametric test in multiple sclerosis by fotometric strategies. 

• Neurological syndromes associated to antiGAD antibodies

• Paraneoplasic syndromes and other neurological diseases associated to antibodies. 

• Study of neurological symptoms after COVID19 recovery in patients refer to specific consutation

• Analysis of brain volumetry in patients with cognitive symptoms after COVID19  

• COVID-19 associated encephalopathy. Risk factors and outcomes

• Evaluation of the Autonomic Nervous System in movement disorders.

• Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.

• COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

• Develop a hand thermography tool for the diagnosis of fine fiber neuropathy.

• Amyotrophic Lateral Sclerosis (ALS)

• Analysis of the different profiles of cognitive impairment in ALS patients.Adaptation and validation of cognitive ALS specific scales for Spanish patients .Study of cognitive potentials  for identification of possible specific EEG endophenotypes in ALS patients.

• Participation In Project MinE: International program  analyzing the  genoma of 15000 patients and controls by the same genotyping platform.

• Participation in clinical trials in Myasthenia Gravis.

• Participation in the National Registry of Pompe disease.

• Development of ultrasonography techniques in neuromuscular diseases.

• Development and evaluation of intervention protocols in childhood insomnia treatment.

• Analysis of sleep microstructure in newborns with Prader Willi Syndrome.

• Study on the efficacy of child insomnia treatment with oral iron supplements against placeb.

• Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsia.

• Analysis of neuropsychological disorders in the primary generalized epilepsy.

• Obstructive sleep apnea in Epilepsy.

• Impact of perampanel in patients with epileptic encephalopathies. A multicentric study. 

• Approach to refractory status epilepticus. Analysis of the different anesthetic agents commonly used in an intensive care unit

• Epilepsy in the elderly patient: peculiarieties and treatment alternatives, with a special focus in refractory cases. 

• Objective assessment of motor or other functional deficits (stroke, movement disorders, multiple sclerosis)

• Environmental enrichment to promote early stroke recovery

• Virtual reality in promoting cognitive and motor recovery

• New applications of ultrasound for diagnosis and research in neurological diseases

• Artificial Intelligence applied to diagnosis and clinical management

• Neurostimulation in brain and spinal cord injuries

• Study and functional classification of the gait of pediatric patients with cerebral palsy.

• Study and functional classification of the gait of patients with familial spastic paraparesis.

• Gait analysis as a tool for the differential diagnosis bet - ween child cerebral palsy and PEF in paediatric patients.

• Therapies with trophic factors, stem cells and extracellular vesicles.

• Biomarkers of damage and repair in neurological diseases

• Ultrasound monitoring and visualization of the brain and peripheral organs in animal models.

 

• Cerebrovascular diseases.

• Headache and neuropathic pain.

• Neurodegenerative diseases: cognitive disorders, movement disorders and spinocerebellar ataxias. 

• Neuroimmunology. Multiple sclerosis..

• Neuromuscular diseases. Motor neuron diseases Amyotrophic lateral sclerosis.

• Digital Technologies applied to neurological diseases

• Neurostimulation in brain and spinal cord injuries

• Developmental disorders and neurological maturation (TRADESMA).

• Brain plasticity and repair after cerebral damage. Traslational research